-
1
-
-
0031561774
-
Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-fluorouracil in plasma
-
Anderson D, Kerr DJ, Blesing C, Seymour LW (1997) Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta- alanine and 5-fluorouracil in plasma. J Chromatogr B Biomed Sci Appl 688:87-93
-
(1997)
J Chromatogr B Biomed Sci Appl
, vol.688
, pp. 87-93
-
-
Anderson, D.1
Kerr, D.J.2
Blesing, C.3
Seymour, L.W.4
-
2
-
-
0031838984
-
Oxaliplatin plus 5-fluorouracil: Clinical experience in patients with advanced colorectal cancer
-
Bleiberg H, de Granmont A (1998) Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32-39
-
(1998)
Semin Oncol
, vol.25
, pp. 32-39
-
-
Bleiberg, H.1
De Granmont, A.2
-
4
-
-
0242720707
-
Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer
-
Cattel L, La Grotta G, Infante L, Passera R, Arpicco S, Brusa P, Bumma C (2003) Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. Farmaco 58:1333-1338
-
(2003)
Farmaco
, vol.58
, pp. 1333-1338
-
-
Cattel, L.1
La Grotta, G.2
Infante, L.3
Passera, R.4
Arpicco, S.5
Brusa, P.6
Bumma, C.7
-
5
-
-
33644549883
-
Prevalence of the IVS14 + IG > a mutation of dihydropyrimidine dehydrogenase gene
-
Chang HM, Kim TW, Ryu MH, Lee H (2004) Prevalence of the IVS14 + IG > A mutation of dihydropyrimidine dehydrogenase gene. Cancer Res Treat 36(Suppl 1):42
-
(2004)
Cancer Res Treat
, vol.36
, Issue.1 SUPPL.
, pp. 42
-
-
Chang, H.M.1
Kim, T.W.2
Ryu, M.H.3
Lee, H.4
-
6
-
-
0033766638
-
Oxaliplatin: A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
-
Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drug 60:895-924
-
(2000)
Drug
, vol.60
, pp. 895-924
-
-
Culy, C.R.1
Clemett, D.2
Wiseman, L.R.3
-
7
-
-
0031890613
-
Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis
-
Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P, Milano G (1998) Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 34:92-97
-
(1998)
Eur J Cancer
, vol.34
, pp. 92-97
-
-
Etienne, M.C.1
Chatelut, E.2
Pivot, X.3
Lavit, M.4
Pujol, A.5
Canal, P.6
Milano, G.7
-
9
-
-
0030967259
-
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients
-
Gamelin E, Bouil AL, Boisdron-Celle M, Turcant A, Delva R, Cailleux A, Krikorian A, Brienza S, Cvitkovic E, Robert J, Larra F, Allain P (1997) Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res 3:891-899
-
(1997)
Clin Cancer Res
, vol.3
, pp. 891-899
-
-
Gamelin, E.1
Bouil, A.L.2
Boisdron-Celle, M.3
Turcant, A.4
Delva, R.5
Cailleux, A.6
Krikorian, A.7
Brienza, S.8
Cvitkovic, E.9
Robert, J.10
Larra, F.11
Allain, P.12
-
10
-
-
0001704606
-
Phase III trail of 5-fluorouracil, folinic acid and with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer
-
Giacchetti S, Zidani R, Perpoint B, Pinel MC, Faggiulo R, Focan C, Letourneau Y, Chollet P, Llory JF, Coudet B, Bertheault-Cvitkovic F, Adam R, Le Baif N, Misset JL, Bayssas M, Levi F (1997) Phase III trail of 5-fluorouracil, folinic acid and with or without oxaliplatin in previously untreated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol Annu Meet 16:A229
-
(1997)
Proc Am Soc Clin Oncol Annu Meet
, vol.16
-
-
Giacchetti, S.1
Zidani, R.2
Perpoint, B.3
Pinel, M.C.4
Faggiulo, R.5
Focan, C.6
Letourneau, Y.7
Chollet, P.8
Llory, J.F.9
Coudet, B.10
Bertheault-Cvitkovic, F.11
Adam, R.12
Le Baif, N.13
Misset, J.L.14
Bayssas, M.15
Levi, F.16
-
11
-
-
0034006524
-
Clinical pharmacokinetics of oxaliplatin: A critical review
-
Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205-1218
-
(2000)
Clin Cancer Res
, vol.6
, pp. 1205-1218
-
-
Graham, M.A.1
Lockwood, G.F.2
Greenslade, D.3
Brienza, S.4
Bayssas, M.5
Gamelin, E.6
-
12
-
-
0034913184
-
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
-
Grem JL, Quinn M, Ismail AS, Takimoto CH, Lush R, Liewehr DJ, Steinberg SM, Balis FM, Chen AP, Monahan BP, Harold N, Corse W, Pang J, Murphy RF, Allegra CJ, Hamilton JM (2001) Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemother Pharmacol 47:117-125
-
(2001)
Cancer Chemother Pharmacol
, vol.47
, pp. 117-125
-
-
Grem, J.L.1
Quinn, M.2
Ismail, A.S.3
Takimoto, C.H.4
Lush, R.5
Liewehr, D.J.6
Steinberg, S.M.7
Balis, F.M.8
Chen, A.P.9
Monahan, B.P.10
Harold, N.11
Corse, W.12
Pang, J.13
Murphy, R.F.14
Allegra, C.J.15
Hamilton, J.M.16
-
13
-
-
0025058867
-
Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion
-
Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201
-
(1990)
Cancer Res
, vol.50
, pp. 197-201
-
-
Harris, B.E.1
Song, R.2
Soong, S.J.3
Diasio, R.B.4
-
14
-
-
3042568991
-
Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin
-
Joel SP, Papamichael D, Richards F, Davis T, Aslanis V, Chatelut E, Locke K, Slevin ML, Seymour MT (2004) Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther 76:45-54
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 45-54
-
-
Joel, S.P.1
Papamichael, D.2
Richards, F.3
Davis, T.4
Aslanis, V.5
Chatelut, E.6
Locke, K.7
Slevin, M.L.8
Seymour, M.T.9
-
15
-
-
0000321517
-
A multicenter phase II trial of intensified chronotherapy with oxaliplatin, 5-fluorouracil, and folinic acid in patients with previously untreated metastatic colorectal cancer
-
Levi F, Dogliotti L, Perpoint B, Zidani R, Giacchetti S, Chollet P, Le Rol A, Llory JF, Focan C, Kunstlinger F, Adam R, Vannetzel JM, Letourneau Y, Jasmin C, Bismuth H, Misset JL (1997a) A multicenter phase II trial of intensified chronotherapy with oxaliplatin, 5-fluorouracil, and folinic acid in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol Annu Meet 16:A266
-
(1997)
Proc Am Soc Clin Oncol Annu Meet
, vol.16
-
-
Levi, F.1
Dogliotti, L.2
Perpoint, B.3
Zidani, R.4
Giacchetti, S.5
Chollet, P.6
Le Rol, A.7
Llory, J.F.8
Focan, C.9
Kunstlinger, F.10
Adam, R.11
Vannetzel, J.M.12
Letourneau, Y.13
Jasmin, C.14
Bismuth, H.15
Misset, J.L.16
-
16
-
-
0041055512
-
Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer
-
Levi F, Zidani R, Misset JL (1997b) Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 350:681-686
-
(1997)
Lancet
, vol.350
, pp. 681-686
-
-
Levi, F.1
Zidani, R.2
Misset, J.L.3
-
17
-
-
0037041639
-
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene
-
Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR, Van Gennip AH, De Vries EG (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028-1033
-
(2002)
Br J Cancer
, vol.86
, pp. 1028-1033
-
-
Maring, J.G.1
Van Kuilenburg, A.B.2
Haasjes, J.3
Piersma, H.4
Groen, H.J.5
Uges, D.R.6
Van Gennip, A.H.7
De Vries, E.G.8
-
18
-
-
0033950031
-
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
-
Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G (2000) Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45:157-164
-
(2000)
Cancer Chemother Pharmacol
, vol.45
, pp. 157-164
-
-
Massari, C.1
Brienza, S.2
Rotarski, M.3
Gastiaburu, J.4
Misset, J.L.5
Cupissol, D.6
Alafaci, E.7
Dutertre-Catella, H.8
Bastian, G.9
-
19
-
-
0036020649
-
Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics
-
Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485-492
-
(2002)
Pharmacogenomics
, vol.3
, pp. 485-492
-
-
Mattison, L.K.1
Soong, R.2
Diasio, R.B.3
-
20
-
-
0034808681
-
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
-
Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7:2832-2839
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2832-2839
-
-
Raida, M.1
Schwabe, W.2
Hausler, P.3
Van Kuilenburg, A.B.4
Van Gennip, A.H.5
Behnke, D.6
Hoffken, K.7
-
21
-
-
0036052558
-
Cellular and molecular pharmacology of oxaliplatin
-
Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1:227-235
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 227-235
-
-
Raymond, E.1
Faivre, S.2
Chaney, S.3
Woynarowski, J.4
Cvitkovic, E.5
-
22
-
-
0002963473
-
Quantitation of platinum - DNA binding in human tissues following therapeutic levels of drug exposure
-
Reed E, Sauerhoff S, Poirier MC (1988) Quantitation of platinum - DNA binding in human tissues following therapeutic levels of drug exposure. Atom Spectrosc 9:93-95
-
(1988)
Atom Spectrosc
, vol.9
, pp. 93-95
-
-
Reed, E.1
Sauerhoff, S.2
Poirier, M.C.3
-
23
-
-
0000460127
-
Oxaliplatin, tetraplatin, cisplatin and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of National Cancer Institutes's Anticancer Drug Screen Panel
-
Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of National Cancer Institutes's Anticancer Drug Screen Panel. Biochem Pharmacol 52:1855-1865
-
(1996)
Biochem Pharmacol
, vol.52
, pp. 1855-1865
-
-
Rixe, O.1
Ortuzar, W.2
Alvarez, M.3
Parker, R.4
Reed, E.5
Paull, K.6
Fojo, T.7
-
24
-
-
0042631396
-
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study
-
Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL, National Cancer Institute Organ Dysfunction Working Group Study (2003) Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 21:2664-2672
-
(2003)
J Clin Oncol
, vol.21
, pp. 2664-2672
-
-
Takimoto, C.H.1
Remick, S.C.2
Sharma, S.3
Mani, S.4
Ramanathan, R.K.5
Doroshow, J.6
Hamilton, A.7
Mulkerin, D.8
Graham, M.9
Lockwood, G.F.10
Ivy, P.11
Egorin, M.12
Schuler, B.13
Greenslade, D.14
Goetz, A.15
Knight, R.16
Thomas, R.17
Monahan, B.P.18
Dahut, W.19
Grem, J.L.20
more..
-
25
-
-
0032974922
-
Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
-
Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GP, Jakobs C, Smit LM, Van Gennip AH (1999) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104:1-9
-
(1999)
Hum Genet
, vol.104
, pp. 1-9
-
-
Van Kuilenburg, A.B.1
Vreken, P.2
Abeling, N.G.3
Bakker, H.D.4
Meinsma, R.5
Van Lenthe, H.6
De Abreu, R.A.7
Smeitink, J.A.8
Kayserili, H.9
Apak, M.Y.10
Christensen, E.11
Holopainen, I.12
Pulkki, K.13
Riva, D.14
Botteon, G.15
Holme, E.16
Tulinius, M.17
Kleijer, W.J.18
Beemer, F.A.19
Duran, M.20
Niezen-Koning, K.E.21
Smit, G.P.22
Jakobs, C.23
Smit, L.M.24
Van Gennip, A.H.25
more..
|